Meeting
2024 ASCO Annual Meeting
Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a physician survey in five European countries (Eu5).
Authors
Shilpa Gupta
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Shilpa Gupta , Thomas Powles , Mairead Kearney , Laura Panattoni , Natalie Land , Thomas Flottemesch , Patrick Sullivan , Melissa Kirker , Murtuza Bharmal , Silke Guenther , Nuno Costa , Enrique Grande
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4570)
DOI
10.1200/JCO.2024.42.16_suppl.4570
Abstract #
4570
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A meta-analysis assessing objective response rates with first-line systemic treatment options in locally advanced/metastatic urothelial carcinoma.
First Author: Akshat Saxena
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.
First Author: Alina Pascale
Poster
2023 ASCO Annual Meeting
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).
First Author: Miriam Koopman
Poster
2023 ASCO Genitourinary Cancers Symposium
Cross-sectional study of patients' (pts) and physicians' needs and the financial toxicity of systemic treatment for metastatic renal cell carcinoma (mRCC) in Japan.
First Author: Takahiro Osawa